Vol.

No.

October 24, 2025Oct 24, 2025

DOWNLOAD THE PDF

Friends study points to ctDNA’s potential to serve as an intermediate endpoint in NSCLC ctMoniTR project aims to improve efficiency in development of intermediate endpoints

Cover Story

Regulatory News

Friends study points to ctDNA’s potential to serve as an intermediate endpoint in NSCLC

ctMoniTR project aims to improve efficiency in development of intermediate endpoints

By Jacquelyn Cobb

New research led by Friends of Cancer Research demonstrates that decreases in circulating tumor DNA after initiation of treatment are associated with improved overall survival in patients with advanced non-small cell lung cancer treated with immunotherapy or chemotherapy.

Duke brain cancer researcher Kyle Walsh named director of NIEHS

By Paul Goldberg

Clinical

GRAIL to use new study results to seek FDA approval of Galleri MCD test

By Jacquelyn Cobb

Omar Abdel-Wahab, John Byrd, Lieping Chen, Robert Ferris, Wendy Garrett, Victor Velculescu are among new members of National Academy of Medicine

By Paul Goldberg

Clinical Trials & Tribulations

Experts warn that loss of carcinogen surveillance threatens to increase cancer incidence

By David M. DeMarini, Rosalie Elespuru, Miriam C. Poirier and Errol Zeiger

Cancer Policy

Shutdown precluded NCI officials from appearing at AACI/CCAF annual meeting

Science advocates organize march in DC to demand impeachment of RFK Jr.

Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA

Federal official claims that temporary order blocking RIFs doesn’t apply to HHS

Insurance premiums set to skyrocket if Congress doesn’t reach a deal

Trump cuts IVF drug deal with Merck in exchange for tariff exemption

In Brief

Korman, Regev, and Rathmell awarded Cancer Research Institute honors in cancer immunotherapy

ACR announces 2026 gold medalists and honorary fellows

Clinical Roundup

Zanzalintinib + atezolizumab improve survival in advanced CRC

Trodelvy reduces risk of disease progression or death by 38% vs. chemo as first-line therapy in metastatic TNBC

Enhertu reduced the risk of disease recurrence or death vs. T-DM1 in high-risk HER2+ early breast cancer following neoadjuvant therapy

Enhertu + THP before surgery resulted in a pathologic complete response in high-risk HER2+ early-stage breast cancer

Keytruda shows long-term survival benefit in NSCLC

Keytruda + Padcev reduced risk of EFS events and death for muscle-invasive bladder cancer when given before and after surgery

Verzenio delivers OS benefit in high-risk early breast cancer

Imfinzi regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer

Imfinzi-based regimen reduced the risk of death in early gastric cancer vs. chemotherapy alone

Tecvayli + Darzalex Faspro improve PFS and OS vs. standard-of-care

GammaTile delivers superior tumor control vs. standard-of-care for newly diagnosed operable brain metastases

Enzalutamide drug combination cuts risk of death in advanced prostate cancer, Cedars-Sinai-led study shows

Drugs & Targets

FDA approves Blenrep combination for relapsed/refractory multiple myeloma after two or more lines of therapy

CHMP adopts positive opinion for Libtayo as adjuvant treatment for high-risk CSCC

CURRENT ISSUE

Recent Issues